Masterflex SE (ISIN: DE0005492938) has reported preliminary results for the 2025 financial year, achieving its forecast and posting new record earnings. The company announced group revenue of EUR 102.6 million, a 4.6% increase from EUR 98.1 million in the previous year. Operating EBITDA rose by 7.4% to EUR 19.5 million (previous year: EUR 18.2 million), while operating EBIT increased by 9.8% to EUR 14.0 million (previous year: EUR 12.7 million). EBIT stood at EUR 13.7 million, up 9.2% from EUR 12.5 million in 2024, within the forecast range of EUR 12 million to EUR 15 million.
The positive performance was driven by the US subgroup and robust demand in medical technology, which increased its share of consolidated revenue from 18% in 2024 to 21% in 2025. Despite economic headwinds in Germany, demand in industrial customer sectors under "Tech" and trading business declined only moderately. The order backlog remained stable at EUR 19.8 million, in line with the previous year.
Masterflex also strengthened its financial position, with an equity ratio improving to 73.3% (previous year: 67.7%). Net debt fell significantly to EUR 2.7 million from EUR 9.0 million, and the debt ratio (net debt/EBITDA) improved to 0.1 (previous year: 0.5).
Dr. Andreas Bastin, CEO of Masterflex SE, commented: "Despite a continuing challenging economic environment, we met our forecasts in the 2025 financial year, achieved solid revenue growth and slightly increased our profitability thanks to continuous efficiency improvements. The development of our medical technology business and the further strengthening of our balance sheet are particularly pleasing."
The preliminary figures are subject to confirmation by auditors and approval by the Supervisory Board. The 2025 consolidated financial statements and the 2026 forecast are scheduled for publication on 31 March 2026. For more information, visit the original release at www.newmediawire.com.
